See more : Yang Guang Co.,Ltd. (000608.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Pulmonx Corporation (LUNG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulmonx Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- Zedge, Inc. (ZDGE) Income Statement Analysis – Financial Results
- Fulgent Genetics, Inc. (FLGT) Income Statement Analysis – Financial Results
- Sartorius Aktiengesellschaft (SRT3.DE) Income Statement Analysis – Financial Results
- Treasury Metals Inc. (TML.TO) Income Statement Analysis – Financial Results
- Anhui Conch Cement Company Limited (AHCHF) Income Statement Analysis – Financial Results
Pulmonx Corporation (LUNG)
About Pulmonx Corporation
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 68.68M | 53.66M | 48.42M | 32.73M | 32.60M | 20.00M |
| Cost of Revenue | 17.92M | 13.80M | 12.79M | 11.53M | 10.18M | 7.72M |
| Gross Profit | 50.75M | 39.87M | 35.63M | 21.20M | 22.41M | 12.29M |
| Gross Profit Ratio | 73.90% | 74.29% | 73.59% | 64.77% | 68.77% | 61.42% |
| Research & Development | 18.08M | 15.40M | 13.06M | 7.46M | 6.05M | 6.99M |
| General & Administrative | 89.81M | 77.01M | 64.77M | 44.57M | 34.20M | 20.35M |
| Selling & Marketing | 4.80M | 6.10M | 5.10M | 1.50M | 600.00K | 100.00K |
| SG&A | 94.61M | 83.11M | 69.87M | 46.07M | 34.20M | 20.35M |
| Other Expenses | 0.00 | -396.00K | -585.00K | 3.28M | -617.00K | -916.00K |
| Operating Expenses | 112.69M | 98.50M | 82.93M | 53.53M | 40.25M | 27.34M |
| Cost & Expenses | 130.61M | 112.30M | 95.72M | 65.07M | 50.43M | 35.06M |
| Interest Income | 5.57M | 1.53M | 400.00K | 213.00K | 432.00K | 21.00K |
| Interest Expense | 3.23M | 1.07M | 829.00K | 3.18M | 2.32M | 2.52M |
| Depreciation & Amortization | 1.95M | 4.00M | 3.16M | 400.00K | 1.20M | 270.00K |
| EBITDA | -55.09M | -55.99M | -46.62M | -28.44M | -16.82M | -15.68M |
| EBITDA Ratio | -80.22% | -107.16% | -98.09% | -88.10% | -54.17% | -78.37% |
| Operating Income | -61.94M | -58.64M | -47.30M | -32.33M | -17.84M | -15.05M |
| Operating Income Ratio | -90.19% | -109.27% | -97.70% | -98.77% | -54.73% | -75.24% |
| Total Other Income/Expenses | 1.66M | 67.00K | -1.01M | 314.00K | -2.50M | -3.42M |
| Income Before Tax | -60.27M | -58.57M | -48.32M | -32.02M | -20.34M | -18.47M |
| Income Before Tax Ratio | -87.76% | -109.15% | -99.80% | -97.82% | -62.40% | -92.32% |
| Income Tax Expense | 571.00K | 353.00K | 343.00K | 213.00K | 363.00K | 12.00K |
| Net Income | -60.84M | -58.92M | -48.66M | -32.23M | -20.70M | -18.48M |
| Net Income Ratio | -88.60% | -109.80% | -100.51% | -98.47% | -63.52% | -92.38% |
| EPS | -1.60 | -1.59 | -1.35 | -0.90 | -0.58 | -0.89 |
| EPS Diluted | -1.60 | -1.59 | -1.35 | -0.90 | -0.58 | -0.89 |
| Weighted Avg Shares Out | 37.97M | 37.10M | 36.13M | 35.69M | 35.43M | 20.71M |
| Weighted Avg Shares Out (Dil) | 37.97M | 37.10M | 36.13M | 35.69M | 35.43M | 20.71M |
Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial
Pulmonx Corporation (LUNG) Q4 2023 Earnings Call Transcript
Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
Pulmonx to Present at the Piper Sandler 35th Annual Healthcare Conference
The Prognosis For Pulmonx Corporation
Pulmonx to Participate at Upcoming Investor Conferences
Pulmonx Corporation (LUNG) Q3 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports